THE NEED FOR REAL-WORLD DATA ON LUNG CANCER MANAGEMENT IN THE ERA OF PRECISION MEDICINE

Dal: 17/05/2024 al: 18/05/2024
Evento Residenziale
GALLIPOLI (LE), Hotel Costa Brada
Rivolto a: Medico Chirurgo ( Anatomia Patologica, Chirurgia Toracica, Malattie dell'apparato Respiratorio, Oncologia, Radioterapia )
Most lung cancer cases correspond to non-small cell lung cancer (NSCLC). To date, a limited percentage of NSCLC cases are diagnosed in the early stage (in which patients are potential candidates for surgery, possibly followed by chemotherapy to reduce the risk of recurrence) or in the locally advanced stage (in which the treatment is based on the use of chemotherapy, radiotherapy and possibly, upon their completion, immunotherapy). The therapeutic strategy in patients with advanced NSCLC has changed in recent years. Until about ten years ago, chemotherapy was the only option available, however, characterised by limited effectiveness. In recent years, the two crucial therapeutic “revolutions” that we have witnessed in medical oncology (molecularly targeted drugs first and then immunotherapy) have played an essential role in treating these patients.
Molecular analyses aimed at identifying the alterations on the tumour tissue represent a fundamental part of the diagnosis today, which precedes the best treatment choice for each patient.
Globally, there is an increasing trend to use real-world data (RWD) to inform decision-making in healthcare, and patient registries are regarded as a typical example of RWD. A patient registry can be defined as “an organised system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves one or more predetermined scientific and clinical purposes. To this end, the information collected in patient registries can extend from appropriate treatment strategies to effectiveness and cost- effectiveness in real-world clinical practice.
Furthermore, achieving and maintaining optimal well-being and health-related quality of life (HRQoL) has become an essential objective of current cancer treatment. The availability of patient-reported outcomes (PROs) is critical for achieving these goals. PROs were collected up to now using paper-and-pencil questionnaires, with suboptimal response rates, costs and overall efficiency of the process. Online administration of questionnaires has several advantages compared to paper-and-pencil questionnaires, including convenience for the participant, potentially significant cost savings, efficiency in data collection, and high quality of the data.
We, therefore, developed a web-based registry for collecting longitudinal data on the clinical, psychosocial and economic impact of lung cancer treatment in Italy.
In this event the topic of the “lung cancer disease” is discussed from various points of view by an Italian and European Faculty and the preliminary results of the Registry developed by us are reported.
Sede Evento
GALLIPOLI (LE), Hotel Costa Brada
Segreteria Organizzativa
Delphi International Srl
Telefono Referente
+39 0532595011
Hai bisogno di aiuto con l'iscrizione, o desideri ulteriori informazioni?
Contattaci